Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called
amyloid in the heart tissue. This makes it difficult for the heart to function properly. The
investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that
targets beta amyloid can also identify cardiac amyloid deposition.